Cohance Lifesciences Ltd - 543064 - Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
Cohance Lifesciences' promoters, Berhyanda Limited and Jusmiral Holdings Limited, have pledged 54.36% of the company's total equity shares (20.79 crore shares) as security for term loan facilities. This action, effective June 17, 2026, indicates increased leverage at the promoter level.
Jun 19 2026 12:32:39
Cohance Lifesciences Ltd - 543064 - Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
Cohance Lifesciences' promoters, Berhyanda Limited and Jusmiral Holdings Limited, have created an encumbrance over 21.99 crore equity shares, which is 57.49% of the company's total share capital. This encumbrance became effective on June 16, 2026, as part of loan facilities.
Jun 19 2026 11:30:24
Cohance Lifesciences Ltd - 543064 - Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011.
Cohance Lifesciences' promoters, Jusmiral Holdings and Berhyanda Limited, created a pledge over 20.8 crore equity shares (54.36% of total share capital). This action secures a USD 285 million term loan facility, with the pledges effective from June 16, 2026.
Jun 18 2026 15:42:36
Cohance Lifesciences Ltd - 543064 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
Cohance Lifesciences promoters Jusmiral Holdings and Berhyanda Limited announced the release of encumbrance on their entire shareholdings, representing 24.15% and 33.34% of total share capital. This action follows the repayment of a loan under a notes purchase agreement.
Jun 18 2026 15:31:20
Cohance Lifesciences Ltd - 543064 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
Cohance Lifesciences' promoters, Jusmiral Holdings Limited and Berhyanda Limited, created new pledges on 54.36% of the company's total shares. This action is part of securing a USD 285 million term loan facility.
Jun 18 2026 15:29:08
Cohance Lifesciences Ltd - 543064 - Announcement under Regulation 30 (LODR)-Resignation of Director
Cohance Lifesciences announced that Mr. Himanshu Agarwal has resigned from his positions as Whole-time Director and Chief Financial Officer. His resignation is effective September 13, 2026, as he pursues professional opportunities outside the organization.
Jun 17 2026 22:33:24
Cohance Lifesciences Ltd - 543064 - Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot
Cohance Lifesciences shareholders approved all 5 postal ballot resolutions. Key approvals include the appointment of Mr. Umang Vohra as Chairman/CEO, his remuneration, and the Employee Stock Option Plan 2026, including its extension to subsidiaries and grants exceeding 1% of capital.
Jun 14 2026 23:40:54
Read More